# **Reproducible diagnostic metabolites in plasma from typhoid fever patients in Asia and Africa**

Elin Näsström 1, Christopher M Parry 2,3, Nga Tran Vu Thieu 4, Rapeephan R Maude 5,

Hanna K de Jong 6, Masako Fukushima 7, Olena Rzhepishevska 1 Florian Marks 8, Ursula Panzner 8,

Justin Im 8, Hyonjin Jeon 8, Seeun Park 8, Zabeen Chaudhury 9, Aniruddha Ghose 9, Rasheda Samad 9,

Tan Trinh Van 4, Anders Johansson 10, Arjen M Dondorp 5, Guy E Thwaites 4,11, Abul Faiz 12,

Henrik Antti 1\* andStephen Baker 4,11,13\*

1 Department of Chemistry, Computational Life Science Cluster, Umeå University, Umeå, Sweden

2 The London School of Hygiene and Tropical Medicine, London, United Kingdom

3 School of Tropical Medicine and Global Health, Department of Clinical Research, Nagasaki University,

Nagasaki, Japan

4 The Hospital for Tropical Diseases, Wellcome Trust Major Overseas Programme, Oxford University

Clinical Research Unit, Ho Chi Minh City, Vietnam

5 Mahidol-Oxford Tropical Medicine Research Unit (MORU), Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand

6 Department of Internal Medicine, Division of Infectious Diseases and Center for Infection and Immunity Amsterdam (CINIMA), and Center for Experimental Molecular Medicine (CEMM), Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands

7 Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, United Kingdom

8 The International Vaccine Institute, Seoul, South Korea

9 Chittagong Medical College Hospital, Chittagong, Bangladesh

10 Department of Clinical Microbiology, Umeå University, Umeå, Sweden

11 Centre for Tropical Medicine, Oxford University, Oxford, United Kingdom

12 Malaria Research Group and Dev Care Foundation, Bangladesh

13 The Department of Medicine, The University of Cambridge, Cambridge, United Kingdom

\*Corresponding authors: Professor Stephen Baker, the Hospital for Tropical Diseases, 764 Vo Van Kiet, Quan 5, Ho Chi Minh City, Vietnam. Tel: +84 89241761. sbaker@oucru.org and Dr Henrik Antti, Department of Chemistry, Computational Life Science Cluster, Umeå University, SE-901 97 Umeå, Sweden. Tel: +46 722084081. henrik.antti@chem.umu.se

***Short title***

Metabolite profiling of typhoid fever

***Key words***

Metabolomics, mass spectrometry, two-dimensional gas chromatography, pattern recognition, chemometrics, enteric fever, typhoid fever, *Salmonella* Typhi, Asia, Africa, diagnostics, biomarkers, urine biomarkers

**Abstract**

*Salmonella* Typhi is the causative agent of typhoid. Typhoid is diagnosed by blood culture, a method that lacks sensitivity, portability and speed. We have previously shown that serovar specific metabolomic profiles can be detected in the blood of typhoid patients from Nepal (Näsström *et al*. 2014). Here, we performed mass spectrometry on plasma from Bangladeshi and Senegalese patients with culture confirmed typhoid fever, clinically suspected typhoid, and other febrile diseases including malaria. After applying supervised pattern recognition modelling we could significantly distinguish metabolite profiles in plasma from the culture confirmed typhoid patients. After comparing the direction of change and degree of multivariate significance, we identified 24 metabolites that were consistently up or down regulated in a further Bangladeshi/Senegalese validation cohort, and the Nepali cohort from our previous work. We have identified and validated a metabolite panel that can distinguish typhoid from other febrile diseases, thus providing a new approach for typhoid diagnostics.

# **Introduction**

Typhoid is a systemic infection caused by the bacterium Salmonella Typhi (*S.* Typhi) [1,2]. With an estimated 21 million cases annually, typhoid remains a persistent global health issue [3,4]. The symptoms of typhoid arise after the organism invades the gastrointestinal wall and enters the bloodstream [5]. Isolating the organism from the bloodstream is the mainstay of typhoid diagnostics [6,7], but this method lacks sensitivity and researchers are aiming to discover biomarkers that may become a more reliable and rapid approach to diagnosing disease [8]. One approach for discovering biomarkers is metabolomics, a method detecting low molecular weight metabolites in biological materials by mass spectrometry [9]. Our previous work demonstrated that significant and reproducible metabolite profiles could segregate *S.* Typhi cases, *Salmonella* Paratyphi A cases, and asymptomatic controls in a Nepali patient cohort [10]. Further, we found that a combination of six metabolites could define the infecting pathogen in the blood of febrile patients. These data represented a major step forward in the discovery of biomarkers with the potential to be future typhoid diagnostics. We have applied a similar approach with plasma samples collected from febrile patients in Bangladesh and Senegal to further investigate and validate our previous findings.

**Results**

*Plasma metabolites in Bangladeshi typhoid fever patients*

By hierarchical multivariate curve resolution we resolved 394 peaks from the GCxGC-TOFMS data (methods) in 30 plasma samples from febrile patients in Bangladesh (Table 1); after filtering to remove low quality peaks and metabolites with a high run order correlation we detected 236 metabolite peaks suitable for modelling. Of the detected metabolite peaks, 65/236 (27.5%) had a putative annotation, 8/236 (3.4%) had a metabolite class, 32/236 (13.6%) were of uncertain identity, and 131/236 (55.5%) were unknown (Supplementary file 1). Initial modelling of these 236 metabolites revealed one outlying sample in the fever control group, which was excluded. We applied a supervised pattern recognition approach using Orthogonal Partial Least Squares with Discriminant Analysis (OPLS-DA) to differentiate the metabolite profiles between two sample classes (culture positive typhoid patients and fever controls). This model was then used to predict the identity of the individual samples in a third sample class (clinically suspected typhoid). The OPLS-DA model provided excellent predictive power for distinguishing between culture positive typhoid patients and fever controls in the first predictive component using 236 informative primary metabolite features (t[1] and tcv[1]) (*p*=0.006) (Fig. 1a and Supplementary file 2).

*Prediction of culture negative/clinically suspected typhoid fever*

A major challenge in diagnosing typhoid is identifying true typhoid patients but have a negative blood culture result [11]. We observed a significant overlap between the culture negative/clinically suspected typhoid metabolite profiles with both the culture positive group and the fever control group (Fig. 1b). We used the OPLS-DA model that distinguished between the culture positive typhoid patients and the fever controls to predict the clinically suspected typhoid samples. We found that 5/9 plasma samples had a metabolite profile indicative of culture positive typhoid and three exhibited a greater degree of resemblance to fever controls (one indifferent) (Fig. 1b). Notably, 3/5 clinically suspected typhoid samples with a metabolite profile indicative of typhoid were additionally PCR amplification positive for *S*. Typhi in blood (Table 1 and Fig. 1b). We also investigated potential diagnostic typhoid signatures in urine samples from the same patients using UPLC-Q-TOFMS (methods). Examination of 941 putative metabolite peaks obtained from urine using positive ionization an OPLS-DA model resulted in significantly different metabolite profiles between the *S.* Typhi culture positive patients and the fever controls (*p*=0.025) (Fig. S1 and Supplementary file 2).

*Reproducible typhoid metabolite patterns in Bangladeshi and Nepali cohorts*

We next compared informative plasma metabolites of Bangladeshi *S*. Typhi culture positive patients with the metabolites in the *S*. Typhi patients from our previous investigation in Nepal [10]. We found 99 informative metabolites in plasma from both cohorts. Comparing the direction of change and the degree of significance we identified 33 metabolites that were consistently up or down regulated between the culture positive *S.* Typhi patients and fever/asymptomatic controls in the two studies (Supplementary file 3). Fifteen of the 33 metabolites were multivariate significant with a stricter criteria (w\*>| ±SD|) in the Bangladeshi cohort and all 33 metabolites were multivariate significant (w\*>|0.03|) in the Nepali cohort. OPLS-DA models with the 15 multivariate significant metabolites resulted in significant separations between *S.* Typhi culture positive patients and fever controls in the current study (Bangladeshi cohort) (*p*=0.016), and the asymptomatic controls in the previous study (Nepali cohort) (*p*<0.0001) (Fig. 2 and Supplementary file 2). Models based on all 33 correspondingly up or down regulated metabolites could also distinguish the *S.* Typhi culture positive patients from the fever/asymptomatic controls (current study: *p*=0.077, previous study: *p*<0.0001) (Supplementary file 2).

*Typhoid fever metabolites in Bangladeshi and Senegalese validation cohorts*

For further validation, we analysed an additional 54 plasma samples from febrile patients from Bangladesh and Senegal using a different analytical technique (GC-TOFMS, methods). This validation cohort included samples from patients with confirmed typhoid and samples from patients with malaria or infections caused by other pathogens. Through an independent targeted processing approach we detected 247 putative metabolites; after manual filtering, 104 metabolites were suitable for modelling (Supplementary file 4). Initially, a three-class OPLS-DA model was obtained indicating the discrimination of typhoid samples from the two control groups (malaria and other pathogens) (Fig. S2 and Supplementary file 2). Furthermore, a two-class OPLS-DA model for separation between typhoid and all control samples together showed significant separation for the new Bangladeshi samples (one overlapping control) and the majority of the Senegalese samples (*p*<0.0001) (Fig. 3a and Supplementary file 2). Malaria presents with a clinical syndrome that can be indistinguishable from typhoid fever; therefore distinguishing between the diseases using their metabolite profiles is an important diagnostic approach. The typhoid samples were compared to the malaria positive samples in a separate OPLS-DA model and showed significant separation (*p*=0.0001), with two overlapping Senegalese typhoid samples, potentially signifying co-infection (Fig. 3b and Supplementary file 2).

The informative plasma metabolites from the Bangladeshi/Senegalese validation cohort were compared to the primary Bangladeshi and Nepali cohorts. We identified 49 common metabolites across all datasets. After comparing the direction of change and degree of multivariate significance, we found 24 metabolites that were consistently up or down regulated in the Bangladeshi/Senegalese validation cohort and the Bangladeshi cohort and/or the Nepali cohort (Supplementary file 4). OPLS-DA models of the consistently up or down regulated metabolites resulted in significant separations between those with typhoid and the control samples for the Bangladeshi/Senegalese validation cohort (*p*<0.0001) (Fig. S3a) and for the Nepali cohort (*p*<0.0001) (Fig. S3c), the model was weaker for the primary Bangladeshi cohort (*p*=0.39) (Fig. S3b) (Supplementary file 2).

**Discussion**

This study augments our previous findings and provides additional insight into next generation typhoid diagnostics [10]. Previously, we aimed to identify metabolite profiles that could distinguish between patients with *S*. Typhi and *S*. Paratyphi A infections. We hypothesised that metabolite profiles might differentiate clinically indistinguishable infections caused by these genetically related pathogens [12,13]; asymptomatic individuals constituted the control group. Here, we aimed to identify *S*. Typhi metabolite profiles in different settings without *S*. Paratyphi A disease [14]. This approach was a greater challenge given a heterogeneous fever control group and a group of patients with suspected typhoid fever. We suggest this study more closely reflects a real situation given the non-specific presentation of febrile diseases. We also assessed the diagnostic potential of urine using this methodology as it is a convenient specimen [6].

Using a validation cohort from Asia and Africa we were able to identify significant, reproducible metabolite profiles in the blood of patients with typhoid. The identified metabolites significantly discriminated *S*. Typhi culture positive individuals from patients with alternative febrile diseases, including malaria. Among patients with clinically suspected typhoid but a negative blood culture we identified metabolite profiles consistent with the confirmed typhoid patient profiles [15]. The metabolite profiles in urine also significantly segregated the typhoid patients from the febrile controls, but did not provide the same predictions as the plasma samples for the culture negative patients. The culture negative clinically suspected typhoid group is challenging because of the lack of a satisfactory reference standard diagnostic test, but this innovative method allows a new approach to investigate this problematic patient group using plasma samples.

The most important finding from this study was the identification and validation of significantly variable metabolites that can identify blood culture confirmed typhoid fever patients in distinct patient cohorts (Asia and Africa) with differing control populations. At least 24 metabolites have the potential to identify typhoid fever patients in these patients. These included glycerol-3-phosphate (carbon source and precursor for phospholipid biosynthesis) [16], stearic acid (component of liposome)[17], and linoleic acid (bactericidal activity) [18], pyruvic acid, and creatinine. Furthermore, leucine and phenylalanine were consistently up or down regulated between all collections.

New approaches are needed for the diagnosis of tropical febrile diseases. We have identified and validated a panel of metabolites that can identify febrile patients with typhoid. The next challenges are to corroborate these targets in larger patient numbers and incorporate into simple diagnostic test formats. This approach could be potentially expanded into other tropical febrile diseases.

# **Methods**

# To measure the systemic metabolite profiles associated with typhoid we selected plasma and urine samples from 30 patients in a febrile disease study conducted in Chittagong, Bangladesh [11]: Ten patients had blood culture *S.* Typhi confirmed typhoid; 9 patients had a clinical diagnosis of typhoid (blood culture negative +/- PCR positive for *S*. Typhi); and 11 matched individuals had a febrile disease other than typhoid (fever controls) (Table 1). The study sites, population and study design are described in detail in the supplementary information and are published elsewhere [11]. Validation samples included plasma samples from 54 patients from Bangladesh and Senegal with 14 patients having confirmed *S*. Typhi infection, 15 patients having malaria and 25 having an infection caused by other bacteria/pathogens (Supplementary file 5). Chromatograms and mass spectra of the Bangladeshi plasma samples were generated and analysed as previously described by blinded operator in a random order using Comprehensive Two-Dimensional Gas Chromatography with Time-of-Flight Mass Spectrometry (GCxGC-TOFMS) [10]. Chromatograms and mass spectra of urine samples were generated using High Throughput Ultra-Performance Liquid Chromatography/Quadrupole-Time-of-Flight Mass Spectrometry (UPLC-Q-TOFMS). Chromatograms and mass spectra of the Bangladeshi/Senegalese validation plasma samples were generated using One-Dimensional Gas Chromatography with Time-of-Flight Mass Spectrometry (GC-TOFMS). Acquired and processed data was analysed using chemometrics based pattern recognition. All methods are described in detail in Supplementary file 6.

**Supplementary information**

**Supplementary file 1**

Table of detected metabolites in plasma samples analysed with GCxGC-TOFMS in the primary Bangladeshi cohort

**Supplementary file 2**

Overview of multivariate models

**Supplementary file 3**

Table of common metabolites between the Bangladeshi and the previous Nepali cohort using OPLS-DA models of culture positive typhoid infection vs. control

# **Supplementary file 4**

# Table of detected metabolites in plasma samples analysed with GC-TOFMS in the Bangladeshi/Senegalese validation cohort

# **Supplementary file 5**

# Additional patient metadata and diagnoses

# **Supplementary file 6**

Additional materials and methods

**Declaration of interests**The authors declare no competing interests.

**Acknowledgements**

This project was funded by the Wellcome Trust of Great Britain (106158/Z/14/Z). Stephen Baker is a Sir Henry Dale Fellow, jointly funded by the Wellcome Trust and the Royal Society (100087/Z/12/Z). Henrik Antti is funded by the Swedish Research Council (VR-U 2015-03442).

**References**

1. Parry CM, Hien TT, Dougan G, White NJ, Farrar JJ (2002) Typhoid fever. N Engl J Med 347: 1770–1782.

2. Dougan G, Baker S (2014) Salmonella enterica serovar Typhi and the pathogenesis of typhoid fever. Annu Rev Microbiol 68: 317–336.

3. Buckle GC, Walker CLF, Black RE (2012) Typhoid fever and paratyphoid fever: Systematic review to estimate global morbidity and mortality for 2010. J Glob Health 2: 10401.

4. Ochiai RL, Acosta CJ, Danovaro-holliday MC, Baiqing D, Bhattacharya SK, et al. (2008) A study of typhoid fever in five Asian countries : disease burden and implications for controls. Bull World Health Organ 39818. doi:10.2471/BLT.06.039818.

5. Everest P, Wain J, Roberts M, Rook G, Dougan G (2001) The molecular mechanisms of severe typhoid fever. Trends Microbiol 9: 316–320.

6. Gilman RH, Terminel M, Levine MM, Hernandez-Mendoza P, Hornick RB (1975) Relative efficacy of blood, urine, rectal swab, bone-marrow, and rose-spot cultures for recovery of Salmonella typhi in typhoid fever. Lancet 1: 1211–1213.

7. Parry CM, Wijedoru L, Arjyal A, Baker S (2011) The utility of diagnostic tests for enteric fever in endemic locations. Expert Rev Anti Infect Ther 9: 711–725.

8. Baker S, Favorov M, Dougan G (2010) Searching for the elusive typhoid diagnostic. BMC Infect Dis 10: 45.

9. Madsen R, Lundstedt T, Trygg J (2010) Chemometrics in metabolomics--a review in human disease diagnosis. Anal Chim Acta 659: 23–33.

10. Näsström E, Thieu Nga TV, Dongol S, Karkey A, Voong Vinh P, et al. (2014) Salmonella Typhi and Salmonella Paratyphi A elaborate distinct systemic metabolite signatures during enteric fever. Elife: e03100. doi:10.7554/eLife.03100.

11. Moore CE, Pan-Ngum W, Wijedoru LPM, Sona S, Nga TVT, et al. (2014) Evaluation of the diagnostic accuracy of a typhoid IgM flow assay for the diagnosis of typhoid fever in Cambodian children using a Bayesian latent class model assuming an imperfect gold standard. Am J Trop Med Hyg 90: 114–120.

12. Didelot X, Achtman M, Parkhill J, Thomson NR, Falush D (2007) A bimodal pattern of relatedness between the Salmonella Paratyphi A and Typhi genomes: convergence or divergence by homologous recombination? Genome Res 17: 61–68.

13. Maskey AP, Day JN, Phung QT, Thwaites GE, Campbell JI, et al. (2006) Salmonella enterica serovar Paratyphi A and S. enterica serovar Typhi cause indistinguishable clinical syndromes in Kathmandu, Nepal. Clin Infect Dis 42: 1247–1253.

14. Maude RR, de Jong HK, Wijedoru L, Fukushima M, Ghose A, et al. (2015) The diagnostic accuracy of three rapid diagnostic tests for typhoid fever at Chittagong Medical College Hospital, Chittagong, Bangladesh. Trop Med Int Health 20: 1376–1384.

15. Nga TVT, Karkey A, Dongol S, Thuy HN, Dunstan S, et al. (2010) The sensitivity of real-time PCR amplification targeting invasive Salmonella serovars in biological specimens. BMC Infect Dis 10: 125.

16. Austin D, Larson TJ (1991) Nucleotide sequence of the glpD gene encoding aerobic sn-glycerol 3-phosphate dehydrogenase of Escherichia coli K-12. J Bacteriol 173: 101–107. A

17. Galdiero F, Carratelli CR, Nuzzo I, Bentivoglio C, De Martino L, et al. (1994) Beneficial effects of myristic, stearic or oleic acid as part of liposomes on experimental infection and antitumor effect in a murine model. Life Sci 55: 499–509.

18. Yang J, Hou X, Mir PS, McAllister TA (2010) Anti-Escherichia coli O157:H7 activity of free fatty acids under varying pH. Can J Microbiol 56: 263–267.

**Table 1.** Patient group metadata for the Bangladeshi cohort

|  |  |  |  |
| --- | --- | --- | --- |
| **Clinical parameter \*** | **Culture confirmed typhoid a (n=10)d** | **Suspected typhoid b (n=9)** | **Fever controls c  (n=10)** |
| Age (years) | 23 (20-30) | 22 (16-30) | 46 (20-65) |
| Sex (male) | 5 | 6 | 8 |
| Fever duration (days) | 7 (5-11) | 10 (6-12) | 5 (5-9) |
| Abdominal pain | 5 | 5 | 5 |
| Diarrhoea | 5 | 3 | 2 |
| Constipation | 1 | 4 | 2 |
| Vomiting | 5 | 7 | 3 |
| Cough | 2 | 1 | 7 |
| Rash | 0 | 2 | 0 |
| Dysuria | 0 | 0 | 2 |
| Headache | 6 | 4 | 6 |
| Seizure | 0 | 0 | 0 |
| Drowsy | 0 | 2 | 2 |
| Bloody stool/ Melaena | 1 | 0 | 1 |
| Confusion/unconscious | 0 | 1 | 0 |
| Axillary temperature (oC) | 38.6 (38.3-39.4) | 38.9 (38.5-39.4) | 38.6 (38.3-38.9) |
| Pulse (bpm) | 108 (97-114) | 100 (92-110) | 105 (86-123) |
| Jaundice | 0 | 1 | 1 |
| Hepatomegaly | 1 | 2 | 1 |
| Splenomegaly | 0 | 0 | 1 |
| Hb | 11.9 (10.4-12.9 | 12.0 (9.6-12.1) | 12.6 (10.4-14.0) |
| WBC | 6.6 (4.9-8.4) | 7.0 (4.2-8.5) | 14.4 (10.7-21.1) |
| Neutrophils (%) | 79 (70-81) | 70 (63-72) | 80 (78-88) |
| Lymphocytes (%) | 19 (15-26) | 25 (24-33) | 15 (8-18) |
| Monocytes (%) | 2 (2-3) | 2 (2-4) | 2 (2-4) |
| Eosinophils (%) | 1 (1-1) | 1 (1-2) | 1 (1-2) |
| Platelets | 170 (160-232) | 180 (160-265) | 280 (180-320) |
| Urea | 24.6 (21.4-28.0) | 24.1 (22.1-29.5) | 67.9 (21.4-81.2) |
| Creatinine | 0.9 0.6-1.0) | 0.9 (.7-1.0) | 1.6 (0.8-2.4) |
| AST | 101 (47-137) | 51 (33-199) | 32 (16-78) |
| ALT | 93 (48-137) | 36 (28-105) | 31 (20-43) |
| Complicationsd | 2 | 0 | 4 |
| Diede | 0 | 0 | 2 |

\* Median and interquartile range (IQR) for each patient group given for quantitative parameters and number of patients with presence of symptom/characteristics for qualitative parameters.

a Typhoid confirmed by a positive blood culture for *S.* Typhi

b Clinical suspected typhoid fever with a negative blood culture, final diagnoses included: Clinically suspected typhoid with blood PCR amplification positive for *S*. Typhi (3); clinical suspected typhoid (4); clinical suspected typhoid or leptospirosis (1); possible typhoid encephalopathy (1)

c Fever controls included: pneumonia (3), malaria (2), meningitis (2); sepsis (1), cellulitis (1), urinary tract infection (1)

d One sample removed from analysis due to discrepant metabolite profile

d Complications were: gastrointestinal bleeding and severe anaemia requiring transfusion in the typhoid group; respiratory failure, hepatorenal failure, septic shock and cardiopulmonary arrest, coma and cardiopulmonary arrest, and an acute myocardial infarction in the fever controls

e Deaths in this group were associated with sepsis and malaria

**Figure legends**

**Figure 1.** OPLS-DA model of plasma metabolites from a Bangladeshi cohort of patients with culture positive typhoid and fever controls, with prediction of suspected typhoid

a) OPLS-DA model generated from GCxGC-TOFMS data from the plasma of 10 patients with culture positive typhoid and 10 fever controls using 236 metabolites. Regular (circles) and cross-validated (squares) scores for the first predictive component (t[1] and tcv[1], respectively, linked by broken line) showing a separation between culture positive typhoid (red) and fever control samples (grey) (*p*=0.006). b)Column plot of the predicted scores for the first predictive component (tPS[1]) where clinically suspected typhoid samples (n=9) (blue columns) have been predicted into the model distinguishing between culture positive typhoid (red) and fever control samples (grey). Plot shows five samples were more similar to the culture positive typhoid samples and three more similar to the controls; one sample remained marginal. The blue stars identify PCR amplification positive samples.

**Figure 2.** The identification and validation of typhoid diagnostic metabolites

OPLS-DA models generated from GCxGC-TOFMS data using 15 informative metabolites from the current study (Bangladeshi cohort) and the previous study in Nepali cohort that were consistently up or down regulated and significantly different in a multivariate model separating culture positive *S.* Typhi patients from controls. a) Regular (circles) and cross-validated (squares) scores for the first predictive component (t[1] and tcv[1], respectively, linked by broken line) showing a separation between culture positive typhoid (red; n=10) and fever control samples (grey; n=10) (*p*=0.016) in the Bangladeshi cohort. b) Column plot of model covariance loadings (w\*[1]) for the first predictive component for the 15 common named metabolites in the Bangladeshi cohort, showing metabolites with a higher relative concentration in the culture positive typhoid group in red and metabolites with a higher relative concentration in the fever control group in grey. c) Regular (circles) and cross-validated (squares) scores for the first predictive component (t[1] and tcv[1], respectively, linked by broken line) showing a separation between culture positive typhoid (red; n=33 including 8 analytical replicates) and afebrile control samples (grey; n=32 including 7 analytical replicates) (*p*<0.0001) from the Nepali cohort. d) Column plot of model covariance loadings (w\*[1]) for the first predictive component for the 15 common named metabolites in the Nepali cohort, showing metabolites with a higher relative concentration in the typhoid group in red and metabolites with a higher relative concentration in the afebrile control group in grey.

**Figure 3.** OPLS-DA models of plasma metabolites from Bangladeshi/Senegalese validation cohorts of patients with typhoid, malaria and other infections

OPLS-DA models generated from GC-TOFMS using 104 metabolites. a) Column plot of the first predictive component scores, t[1] showing a separation of typhoid infection samples (red; n=14) from the two control groups; malaria (lightgrey; n=15) and infections caused by other bacteria/pathogens (grey; n=25) (*p*<0.0001). For the Bangladeshi samples there is a clear separation except for one control sample behaving as a typhoid sample, there is more overlap for the Senegalese samples. b) Column plot of the first predictive component scores, t[1] showing a separation of typhoid infection samples (red; n=14) from malaria samples (lightgrey; n=15) (*p*<0.001). There is a clear separation for the Bangladeshi samples and for the Senegalese samples except two typhoid samples behaving as malaria.

**Supplementary figure legends**

**Figure S1**. OPLS-DA model of urine metabolites from a Bangladeshi cohort including patients with culture positive typhoid and fever controls, with prediction of suspected typhoid

a) OPLS-DA model generated from UHPLC-Q-TOFMS data from the urine of 10 patients with culture positive typhoid and 10 fever controls using 941 metabolites (positive ionization mode). Regular (circles) and cross-validated (squares) scores for the first predictive component (t[1] and tcv[1], respectively, linked by broken line) showing a separation between culture positive typhoid (red) and fever control samples (grey) (p=0.025). b) Column plot of the predicted scores for the first predictive component (tPS[1]) where culture negative/suspected typhoid typhoid samples (n=9) (blue columns) have been predicted into the model distinguishing between culture positive typhoid (red) and fever control samples (grey); PCR amplification positive samples are identified by the blue stars.

**Figure S2.** Three-class OPLS-DA model of GC-TOFMS data of plasma samples from a Bangladeshi/Senegalese validation cohort including patients with typhoid, malaria and other infections based on 104 metabolites

Score plot with the scores of the two first predictive component, t[1] (x-axis) and t[2] (y-axis) showing a separation of typhoid infection samples, shown in red, from the two control groups (malaria, shown in white, and infections caused by other bacteria/pathogens, shown in grey) along the first component (with some overlap) and a separation of the malaria control group from the other infections control group along the second component (with some overlap) (*p*=0.0035).

**Figure S3**. Comparison of metabolites for three sample cohorts

The metabolite pattern separating typhoid samples from controls in the Bangladeshi/Senegalese validation cohort was compared to the corresponding metabolite patterns in the Bangladeshi cohort in the current study and the Nepali cohort in the previous study to find metabolites that were consistently up or down regulated and multivariate significant in the three cohorts. Column plots of first predictive component scores (t[1]) for OPLS-DA models separating typhoid samples from controls for a) GC-TOFMS data of plasma samples from the Bangladeshi/Senegalese validation cohort based on 24 significant metabolites consistently up or down regulated in the Bangladeshi/Senegalese cohort and the Bangladeshi cohort and/or the Nepali cohort (*p*<0.0001), b) GCxGC-TOFMS data of plasma samples from the Bangladeshi cohort based on 13 significant metabolites consistently up or down regulated in the Bangladeshi/Senegalese cohort and the Bangladeshi cohort (*p*=0.39) and c) GCxGC-TOFMS data of plasma samples from the Nepali cohort based on 14 significant metabolites consistently up or down regulated in the Bangladeshi/Senegalese cohort and the Nepali cohort (p<0.0001). 5 metabolites were consistently up or down regulated in all three cohorts.